ALLR supply chain intelligence for Allarity Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Allarity Therapeutics, Inc. (ALLR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| STREETERVILLE-CAPITAL | STREETERVILLE-CAPITAL | 90% | On March 6, 2026, Allarity Therapeutics, Inc. (the “Company”) announced the closing of a $20 million non-convertible debt financing with Streeterville Capital. |
| TUMIN-STONE-CAPITAL-LLC | TUMIN-STONE-CAPITAL-LLC | 80% | the Common Stock Purchase Agreement with Tumin Stone Capital LLC dated January 28, 2026, so long as such agreement is not amended, modified or replaced after the date hereof |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from AZN grap… |
| AZN | AstraZeneca PLC | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to … |
| BMY | Bristol-Myers Squibb Company | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us t… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| KURA | Kura Oncology, Inc. | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| KURA | Kura Oncology, Inc. | 72% | Reciprocal relationship from KURA graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to… |
| SNYNF | Sanofi | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us t… |
| ALUR | Allurion Technologies Inc. | 62% | Reciprocal relationship from ALUR graph: part of these condensed consolidated financial statements. 6 1. Organization and Basis of Presentation Organization Allurion Technologies, Inc. (“Allurion” or… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AZN | AstraZeneca PLC | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to … |
| BMY | Bristol-Myers Squibb Company | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from BMY graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from BMY grap… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from BMYM… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| KURA | Kura Oncology, Inc. | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| KURA | Kura Oncology, Inc. | 72% | Reciprocal relationship from KURA graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from KURA graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in o… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us t… |
| SNYNF | Sanofi | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ALLR-DEBT-7685 | Warrants outstanding: 71734 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| ALLR-DEBT-7686 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-09-30. |
| ALLR-DEBT | Debt stack $2.9M | 90% | Market cache reports total debt of $2.9M. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALUR | Allurion Technologies Inc. | 100.00 | 1 | ['supplier'] |
| SNYNF | Sanofi | 100.00 | 1 | ['customer', 'supplier'] |
| KURA | Kura Oncology, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 1 | ['customer', 'supplier'] |
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['customer', 'supplier'] |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 50.00 | 2 | |
| CEROW | CERO THERAPEUTICS HOLDINGS, INC. | 50.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 50.00 | 2 | |
| CRVS | Corvus Pharmaceuticals, Inc. | 50.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 50.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 50.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 50.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 50.00 | 2 | |
| DNTH | Dianthus Therapeutics, Inc. | 50.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 50.00 | 2 | |
| DEO | Diageo plc | 50.00 | 2 |